AZTR (Azitra) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 26, 2026)


AZTR Azitra Inc AZTR
35 GF Score
Price $0.17
! 1 Warning Sign
View Full Analysis

What is Azitra Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Azitra's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

AZTR vs VIVS, GRI, BIXT: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Azitra's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Azitra Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Azitra's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Azitra's Margin of Safety % (DCF Earnings Based) falls into.


AZTR
35GF Score
Azitra Inc AZTR
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Azitra Business Description

Address 21 Business Park Drive, Branford, CT, USA, 06405
Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.
35GF Score

Get the complete analysis for AZTR

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.17
Price